OncoSec Medical (ONCS), a biotechnology company focused on combination immunotherapies, offered anecdotal evidence last year suggesting its novel approach might help some skin cancer patients who do not benefit from the currently approved class of drugs known as checkpoint inhibitors. What OncoSec lacked was data from a clinical trial to hang its hopes on.
On Tuesday, the company tried to remedy that scientific shortcoming, but the newly released sliver of data on the drug, called Tavo, are frustratingly early and hard to interpret.
How scant? Nine patients with advanced, metastatic melanoma (skin cancer) were treated with a combination of Tavo and Merck’s (MRK) checkpoint inhibitor Keytruda in an ongoing, mid-stage clinical trial. Of these nine patients, two have showed partial tumor responses. These two responses are preliminary, however, because neither of the two patients have been followed long enough to undergo confirmatory scans.
Thank you for your continued watch, regarding this treatment protocol. A very close family member who has been treated with the immunotherapy for a little known melanoma diagnosis of Merkel Cell Carcinoma, had a double surgical procedure, followed with a 37 daily radiation treatment, and then had to endure two more mega doses of radiation for three consecutive Monday’s for the three radiation treatments, plus a three month total body scan ( which was the discovery for the three times that the melanoma cells were discovered again ), and this will possibly be a life long treatment protocol for the rest of the individual’s life, is seemingly helpful for keeping the individual in a full time employment opportunity, with a lot of travel experiences throughout the USA, and Canada. The diagnosis is so new to the medical professionals, has no way to determine whether or not the treatment is necessary for the rest of the individual’s life, along with the three month scans, and pt, with a couple of medications that are prescribed to help the lymphoma system that are the most significant manner of transmission of new carcinoma cells, that require a regime of radiation treatment for the three consecutive Monday’s, is the only way that the individual has, as a hopeful, successful treatment protocol for this little known skin melanoma cells in the patient’s body.
I hope to read more about this topic, because of the rare diagnosis of skin cancer. The lymphatic system is the most vulnerable for the reoccurring issues with this diagnosis.
Well that was piss poor.
Comments are closed.